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Background The global prevalence of ulcerative colitis is increasing, and induction and maintenance of remission is a
crucial therapeutic goal. We assessed the efficacy and safety of filgotinib, a once-daily, oral Janus kinase 1 preferential
inhibitor, for treatment of ulcerative colitis.
Methods This phase 2b/3, double-blind, randomised, placebo-controlled trial including two induction studies and
one maintenance study was done in 341 study centres in 40 countries. Eligible patients were aged 18–75 years with
moderately to severely active ulcerative colitis for at least 6 months before enrolment (induction study A: inadequate
clinical response, loss of response to or intolerance to corticosteroids or immunosuppressants, naive to tumour
necrosis factor [TNF] antagonists and vedolizumab [biologic-naive]; induction study B: inadequate clinical response,
loss of response to or intolerance to any TNF antagonist or vedolizumab, no TNF antagonist or vedolizumab use
within 8 weeks before screening [biologic-experienced]). Patients were randomly assigned 2:2:1 to receive oral
filgotinib 200 mg, filgotinib 100 mg, or placebo once per day for 11 weeks. Patients who had either clinical remission
or a Mayo Clinic Score response at week 10 in either induction study entered the maintenance study. Patients who
received induction filgotinib were rerandomised 2:1 to continue their induction filgotinib regimen or to placebo.
Patients who received induction placebo continued receiving placebo. The primary endpoint was clinical remission
by Mayo endoscopic, rectal bleeding, and stool frequency subscores at weeks 10 and 58. For the induction studies,
efficacy was assessed in all randomised patients who received at least one dose of study drug or placebo within that
study. For the maintenance study, efficacy was assessed in all patients randomised to any filgotinib treatment group
in the induction studies who received at least one dose of study drug or placebo in the maintenance study. Patients
who received placebo throughout the induction and maintenance study were not included in the full analysis set for
the maintenance study. Safety was assessed in all patients who received at least one dose of the study drug or placebo
within each study. This trial is registered with ClinicalTrials.gov, NCT02914522.
Findings Between Nov 14, 2016, and March 31, 2020, we screened 2040 patients for eligibility. 659 patients enrolled in
induction study A were randomly assigned to receive filgotinib 100 mg (n=277), filgotinib 200 mg (n=245), or
placebo (n=137). 689 patients enrolled into induction study B were randomly assigned to receive filgotinib
100 mg (n=285), filgotinib 200 mg (n=262), or placebo (n=142). 34 patients in induction study A and 54 patients in
induction study B discontinued the study drug before week 10. After efficacy assessment at week 10, 664 patients
entered the maintenance study (391 from induction study A, 273 from induction study B). 93 patients continued to
receive placebo. 270 patients who had received filgotinib 100 mg in the induction study were randomly assigned to
receive filgotinib 100 mg (n=179) or placebo (n=91). 301 patients who had received filgotinib 200 mg in the induction
study were randomly assigned to receive filgotinib 200 mg (n=202) or placebo (n=99). 263 patients discontinued
treatment in the maintenance study. At week 10, a greater proportion of patients given filgotinib 200 mg had clinical
remission than those given placebo (induction study A 26·1% vs 15·3%, difference 10·8%; 95% CI 2·1–19·5,
p=0·0157; induction study B 11·5% vs 4·2%, 7·2%; 1·6–12·8, p=0·0103). At week 58, 37·2% of patients given
filgotinib 200 mg had clinical remission versus 11·2% in the respective placebo group (difference 26·0%, 95% CI
16·0–35·9; p<0·0001). Clinical remission was not significantly different between filgotinib 100 mg and placebo at
week 10, but was significant by week 58 (23·8% vs 13·5%, 10·4%; 0·0–20·7, p=0·0420). The incidence of serious
adverse events and adverse events of interest was similar between treatment groups. In the induction studies,
serious adverse events occurred in 28 (5·0%) of 562 patients given filgotinib 100 mg, 22 (4·3%) of 507 patients given
filgotinib 200 mg, and 13 (4·7%) of 279 patients given placebo. In the maintenance study, serious adverse events
were reported in eight (4·5%) of 179 patients given filgotinib 100 mg, seven (7·7%) of 91 patients in the respective
placebo group, nine (4·5%) of 202 patients in the filgotinib 200 mg group, and no patients in the respective placebo
group. No deaths were reported during either induction study. Two patients died during the maintenance study;
neither was related to treatment.
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Interpretation Filgotinib 200 mg was well tolerated, and efficacious in inducing and maintaining clinical remission
compared with placebo in patients with moderately to severely active ulcerative colitis.
Funding Gilead Sciences.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Introduction
The global prevalence of ulcerative colitis is rapidly
increasing.1,2 Ulcerative colitis is an immune-mediated
disease characterised by chronic inflammation of the
colon leading to bloody diarrhoea, frequent bowel
movements, and tenesmus. The pathogenesis of ulcerative
colitis is multifactorial and includes immune, genetic,
environmental, and microbial components.1 Available
treatments for moderately to severely active ulcerative
colitis include corticosteroids, immunosuppressants such
as thiopurines and ciclosporin, tumour necrosis factor
(TNF) antagonists, the anti-integrin vedolizumab, the
interleukin-12/23 antagonist ustekinumab, and the Janus
kinase (JAK) inhibitor tofacitinib.3 A crucial therapeutic
goal is the induction and maintenance of remission,1
defined as both resolution of symptoms and objective
evidence of improvement in the endoscopic appearance
of the colonic mucosa.4 Long-term aims include
minimisation of the risks associated with corticosteroid
exposure, colectomy, and colorectal cancer.1,5 Despite the
advent of targeted treatments, a substantial proportion of
patients do not respond to treatment, lose response over
time, or have adverse events,6 and additional therapeutic
options are therefore needed.
JAK–signal transducers and activators of transcription
pathways are implicated in the pathogenesis of ulcerative
colitis,7–9 and JAK inhibition is effective for the treatment
of ulcerative colitis.10 Filgotinib, an oral JAK1 preferential
inhibitor,11 is in development for the treatment of

inflammatory diseases including ulcerative colitis and
Crohn’s disease. Filgotinib preferentially inhibits JAK1
over JAK2, JAK3, and tyrosine kinase 2,12 and could
thereby confer an improved safety profile.13–15 Filgotinib
has been evaluated in several randomised controlled
trials in patients with rheumatoid arthritis,16–18 psoriatic
arthritis,19 and ankylosing spondylitis.20 In patients with
Crohn’s disease, filgotinib 200 mg was superior to placebo
for induction of clinical remission in the phase 2
FITZROY trial.21 In the phase 2b/3 SELECTION trial, we
aimed to assess the efficacy and safety of filgotinib in
inducing and maintaining remission in patients with
moderately to severely active ulcerative colitis.

Methods

Study design
This phase 2b/3 double-blind, randomised, placebocontrolled trial included two induction studies and
one maintenance study in adults with moderately to
severely active ulcerative colitis from 341 study centres
(clinics, research centres, community centres, and
academic hospitals) in 40 countries (Argentina, Australia,
Austria, Belgium, Bulgaria, Canada, Croatia, Czech
Republic, France, Georgia, Germany, Greece, Hong
Kong, Hungary, India, Ireland, Israel, Italy, Japan,
Malaysia, Mexico, the Netherlands, New Zealand,
Norway, Poland, Portugal, South Korea, Romania, Russia,
Serbia, Singapore, Slovakia, South Africa, Spain, Sweden,
Switzerland, Taiwan, Ukraine, the UK, and the USA).
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Research in context
Evidence before this study
The global prevalence of ulcerative colitis is increasing, and the
field of inflammatory bowel disease is advancing rapidly.
However, despite some available therapies, including one
pan-Janus kinase (JAK) inhibitor, tofacitinib, there remains a
substantial unmet need for effective, well tolerated treatments
for ulcerative colitis. We searched PubMed with the terms
“ulcerative colitis”, “treatment”, and “moderate to severe” to
identify articles in English published from Jan 1, 2016, to
Nov 1, 2020. We found 592 articles describing the treatment of
ulcerative colitis. The efficacy and safety of once-daily oral JAK1
preferential inhibitor filgotinib has been investigated in a
randomised controlled trial in Crohn’s disease.

filgotinib for induction and maintenance of remission in
patients with moderately to severely active ulcerative colitis.
Efficacy relative to placebo was shown for filgotinib 200 mg
once per day for induction and maintenance of remission.
Filgotinib was well tolerated and the incidence of serious
adverse events was not different to placebo.
Implications of all the available evidence
The SELECTION trial provides evidence for the efficacy of
filgotinib in patients with moderately to severely active
ulcerative colitis. Filgotinib could represent a new treatment
option for patients with moderately to severely active
ulcerative colitis who are either naive to biologic therapy or
have had previous treatment with biologics.

Added value of this study
SELECTION was the first randomised, placebo-controlled,
combined phase 2b–3 trial to evaluate the efficacy and safety of
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The final protocol and five amendments were
reviewed and approved by the Independent Ethics
Committee or Institutional Review Board at each study
site. The study was carried out in accordance with
the International Conference on Harmonisation Good
Clinical Practice Guidelines and the Declaration of
Helsinki. A copy of the protocol can be found in the
appendix (p 4).

Participants
Eligible patients were aged 18–75 years at screening and
had a diagnosis of ulcerative colitis with endoscopic and
histopathologic evidence of ulcerative colitis for at least
6 months before enrolment. Patients had moderately
to severely active ulcerative colitis (Mayo endoscopy
subscore ≥2, rectal bleeding subscore ≥1, stool frequency
subscore ≥1, physician’s global assessment subscore ≥2;
total Mayo Clinic Score [MCS] 6–12). Full details of
inclusion and exclusion criteria for all studies are pro
vided in the appendix (p 4).
Eligible patients were enrolled into one of two induction
studies (A and B) based on their experience with TNF
antagonists or vedolizumab. Eligible patients who had
an inadequate clinical response, loss of response to or
intolerance to corticosteroids or immunosuppressants,
and were naive to TNF antagonists and vedolizumab
(biologic-naive) were enrolled in induction study A.
Eligible patients who had an inadequate clinical response,
loss of response to or intolerance to any TNF antagonist or
vedolizumab, and had not used any TNF antagonist or
vedolizumab within 8 weeks before screening (biologicexperienced) were enrolled in induction study B. Patients
who had previously received any JAK inhibitor were
not eligible for either induction study, following an
amendment to the protocol.
Concomitant medications permitted during the
studies were oral 5-aminosalicylic acid, azathioprine,
6-mercaptopurine, methotrexate (if the dose was stable
for 4 weeks before and 10 weeks after randomisation),
and prednisone at a dose of up to 30 mg/day or
budesonide at a dose of up to 9 mg/day (if the dose was
stable for 2 weeks before and 14 weeks after ran
domisation). Starting at week 14, corticosteroids had
to be tapered according to a predefined schedule.
Corticosteroids could be increased in dose or restarted at
doses up to and including the baseline dose if symptoms
returned, according to the investigator’s judgment.
Treatment was considered to have failed for patients
who received corticosteroids at a dose higher than their
baseline dose, but these patients were permitted to
remain in the study.

Randomisation and masking
Patients in induction studies A and B were randomly
assigned (2:2:1) to receive filgotinib or matched
placebo. Efficacy was assessed at week 10, and patients
who had either clinical remission or MCS-defined
2374

response were rerandomised 2:1 at week 11 to continue
their induction filgotinib regimen or to receive placebo
to week 58 (maintenance study). Placebo responders
continued to receive placebo in the maintenance study.
Patients who did not have either clinical remission or
MCS response at week 10 had the option to enter a
separate, long-term extension study (SELECTIONLTE,
NCT02914535). Patients who met disease worsening
criteria in the maintenance study were discontinued
from treatment and offered open-label filgotinib
in SELECTIONLTE (appendix p 7). Patients who
completed week 58 were also eligible for enrolment in
SELECTIONLTE.
Patients were stratified by use of oral systemic
corticosteroids on day 1 and use of immunosuppressants
(6-mercaptopurine, azathioprine, and methotrexate)
on day 1 (induction study A); by the same factors as
induction study A and by previous exposure to one versus
more than one biologic agent (induction study B); and by
the same factors as induction study A and by participation
in induction study A or B in the maintenance study.
Randomisation was done via an interactive web response
system. All people directly involved in the conduct and
analysis of the trial (including patients, investigators,
and study personnel) were fully masked to treatment
allocation before the week 58 database lock. To maintain
masking, study drug appearance, packaging, and labels
were identical irrespective of treatment.

Procedures
Participants were randomly assigned to receive oral
filgotinib (Mayne Pharma, NC, USA, or Rottendorf
Pharma, Ennigerloh, Germany) 200 mg, filgotinib
100 mg, or placebo, once daily for 11 weeks. Doses were
based on the results of the phase 2 FITZROY study in
Crohn’s disease.21 Because of concerns from regulatory
agencies in the USA and South Korea about the potential
effect of filgotinib on semen, men from these countries
for whom two biologic therapies (a TNF antagonist and
vedolizumab) had not failed were randomised (2:1) to
receive filgotinib 100 mg or placebo. Only men for whom
both therapies had failed were randomly assigned to
filgotinib 200 mg or placebo.
Patients recorded symptoms of rectal bleeding and
stool frequency daily in an eDiary. A colonoscopy or
flexible sigmoidoscopy with biopsy was done at baseline,
week 10, and week 58, and centrally read for assessment
of endoscopy and histopathology. Methods pertaining to
central reading are included in the appendix (p 7). Blood
samples for pharmacokinetic assessments were obtained
at weeks 4, 10, 26, and 58, and used to determine plasma
concentrations of filgotinib and its primary metabolite,
GS-829845. Patients who gave their consent to take part
in the optional pharmacokinetic substudy had additional
pharmacokinetic samples obtained before treatment and
at 30 min and 1, 2, 3, 4, and 6 h after supervised dosing
in the clinic visit between week 2 and week 10. Plasma
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concentrations of filgotinib and GS-829845 were
determined as described previously.22,23

Outcomes
Definitions of efficacy endpoints are provided in the panel.
The primary outcome was clinical remission at week 10
and week 58. Clinical remission was defined by use of the
Mayo endoscopic, rectal bleeding, and stool frequency
subscores (the three-component version of MCS, distinct
to the four-component total MCS) in accordance with
regulatory feedback at the time of study design.25,26
Key secondary objectives of the induction studies were
MCS remission, endoscopic remission, histologic
remission, and MCS remission (alternative definition) at
week 10 in induction studies A and B, and at week 58.
6-month corticosteroid-free clinical remission and
sustained clinical remission were also assessed at
week 58 in the maintenance study. Exploratory efficacy
endpoints included MCS response and endoscopic
improvement at week 10 and week 58. Exploratory
endpoints included MCS response, endoscopic improve
ment, and health-related quality of life measures. Details
of these measures and post hoc analyses on speed of
onset of action and corticosteroid-related measures will
be reported separately.
Safety assessments included adverse events, con
comitant medications, laboratory analyses, vital signs,
electrocardiograms, and physical examinations (intervals
differed between variables). The severity of adverse
events and clinical laboratory results were graded by use
of the modified Common Terminology Criteria for
Adverse Events, version 4.03.

Statistical analysis
We estimated that a sample size of 130 in the placebo
group and 260 in each filgotinib group (650 in each
induction study) would provide 90% power for each
filgotinib dose group comparison with placebo at a
two-sided significance level of 0·025, to detect a difference
of 15% in clinical remission rate (25% for filgotinib vs
10% for placebo). Assuming a response rate of 55% in
patients assigned to filgotinib 200 mg or 100 mg in the
induction studies, approximately 285 patients from each
filgotinib dose group from induction study A and B
combined were needed for rerandomisation into the
maintenance study. A sample size of 190 patients in each
filgotinib group and 95 patients in each respective placebo
group in the maintenance study would provide more than
85% power for each filgotinib dose group comparison
with placebo at a two-sided significance level of 0·025,
to detect a difference of 20% in clinical remission rate
(40% for filgotinib vs 20% for placebo).
Efficacy endpoints were analysed by use of the full
analysis sets. For the induction studies, these included
all randomised patients who received at least one dose
of study drug within that study. For the maintenance
study, the full analysis set included all patients

Panel: Efficacy endpoint definitions
Primary endpoint
Clinical remission
• Mayo endoscopic subscore of 0 or 1, rectal bleeding subscore of 0, and at least a
1 point decrease in stool frequency from induction baseline for a subscore of 0 or 1
Key secondary endpoints
Mayo Clinic Score (MCS) remission
• A total MCS of 2 or less and no single subscore higher than 1
MCS remission (alternative definition)
• Rectal bleeding, stool frequency, and physician’s global assessment subscores of 0 and
an endoscopic subscore of 0 or 1; overall MCS of 1 or 0
Endoscopic remission
• Mayo endoscopic subscore of 0
Histologic remission
• Based on the Geboes Scale. No or mild increase in chronic inflammatory infiltrate in
lamina propria, no neutrophils in lamina propria or epithelium, and no erosion,
ulceration, or granulation tissue (Grade 0 of ≤0·3, Grade 1 of ≤1·1, Grade 2a of ≤2A·3,
Grade 2b of 2B·0, Grade 3 of 3·0, Grade 4 of 4·0, and Grade 5 of 5·0)24
6-month corticosteroid-free remission
• Clinical remission with no corticosteroid use for the indication of ulcerative colitis for
at least 6 months before week 58 in patients who were on corticosteroids at baseline
of the maintenance study
Sustained clinical remission
• Clinical remission at both week 10 and week 58
Exploratory endpoints
MCS response
• A reduction of 3 or more points in MCS and at least 30% from induction baseline with
an accompanying decrease in rectal bleeding subscore of 1 point or more, or an
absolute rectal bleeding subscore of 0 or 1
Endoscopic improvement
• Mayo endoscopic subscore of 0 or 1
Health-related quality of life (HRQoL)
• Change from baseline in HRQoL scores; HRQoL measures comprised the 36-Item
Short Form Survey, the Work Productivity and Activity Impairment Questionnaire,
the European Quality of Life 5-Dimension Questionnaire, and the Inflammatory Bowel
Disease Questionnaire
Post hoc analyses
Mucosal healing
• Endoscopic improvement and histologic remission in the same patient

randomised to either filgotinib treatment group in the
induction studies who had clinical remission or an
MCS response at week 10, were rerandomised in the
maintenance study, and who received at least one dose
of study drug in the maintenance period. Patients
who received placebo throughout the induction and
maintenance study were not included in the full
analysis set for the maintenance study. Safety endpoints
were analysed by use of data from all patients who
received at least one dose of the study drug or placebo
within each study.
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The hypothesis testing procedures for the induction
studies and the maintenance study are outlined in the
appendix (p 9). A graphical approach to sequentially
rejective test procedures was used to control a
family-wise type I error rate at 5% (α=0·05) for each
individual study. A Bonferroni approach with equal α
allocation of 0·025 (two-sided) to each filgotinib dose
group comparison with placebo was used to control the
overall study-wide type I error rate at 0·05 within each
study. Because of the unblinded interim futility analysis
for each induction study, an α of 0·00001 was spent for
each filgotinib dose group comparison with placebo
within each induction study. Accordingly, a nominal

p<0·02499 (two-sided) was needed to declare statistical
significance for the final primary analysis of each
filgotinib dose group when compared with placebo in
each induction study. Given that no interim analysis
was planned, the significance level for the final primary
analysis in the maintenance study was set as 0·025
(two-sided) for each filgotinib dose group versus
placebo.
Primary, key secondary, and binary exploratory efficacy
endpoints were analysed by use of stratified CochranMantel-Haenszel tests. A non-responder imputation
approach was used to impute missing values. Separate
comparisons were done between the filgotinib 200 mg

A Induction study A
1090 patients screened

431 excluded*

659 enrolled and randomly assigned

245 assigned to filgotinib 200 mg

277 assigned to filgotinib 100 mg

8 discontinued study drug
4 patient decision
3 adverse events
1 non-compliance with study drug

237 completed study to week 10

137 assigned to placebo

17 discontinued study drug
10 patient decision
5 adverse events
1 lost to follow-up
1 protocol violation

260 completed study to week 10

9 discontinued study drug
4 patient decision
3 adverse events
1 lost to follow-up
1 protocol violation

128 completed study to week 10

B Induction study B
950 patients screened

261 excluded*

689 enrolled and randomly assigned

262 assigned to filgotinib 200 mg

285 assigned to filgotinib 100 mg

20 discontinued study drug
5 patient decision
15 adverse events

242 completed study to week 10

142 assigned to placebo

20 discontinued study drug
3 patient decision
14 adverse events
1 protocol violation
1 investigator discretion
1 pregnancy

265 completed study to week 10

14 discontinued study drug
3 patient decision
10 adverse events
1 protocol violation

128 completed study to week 10

Figure 1: Trial profile
*Validated output for patients who failed screening were not available.
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Age, years

Induction study A: biologic-naive patients

Induction study B: biologic-experienced patients

Placebo
(n=137)

Placebo
(n=142)

41 (12·9)

Filgotinib 100 mg
(n=277)

Filgotinib 200 mg
(n=245)

42 (13·3)

42 (13·1)

44 (14·9)

Filgotinib 100 mg Filgotinib 200 mg
(n=285)
(n=262)
43 (14·3)

43 (14·2)

Sex
Female

50 (36·5%)

120 (43·3%)

122 (49·8%)

56 (39·4%)

99 (34·7%)

114 (43·5%)

Male

87 (63·5%)

157 (56·7%)

123 (50·2%)

86 (60·6%)

186 (65·3%)

148 (56·5%)

Duration of ulcerative colitis, years

6·4 (7·4)

6·7 (7·4)

7·2 (6·9)

10·2 (8·2)

9·7 (7·2)

9·8 (7·6)

Total Mayo Clinic Score

8·7 (1·3)

8·6 (1·4)

8·6 (1·3)

9·3 (1·4)

9·3 (1·3)

9·2 (1·4)

76 (55·5%)

159 (57·4%)

133 (54·3%)

111 (78·2%)

222 (77·9%)

203 (77·5%)

Mayo endoscopy subscore of 3
C-reactive protein, mg/L

5·8 (7·6)

Faecal calprotectin, μg/g

2231 (2917)

7·8 (17·4)
2001 (3448)

8·6 (16·3)
2059 (2639)

14·0 (24·3)
2479 (3571)

11·7 (18·0)
2236 (3095)

12·2 (14·9)
2845 (4077)

Concomitant use of systemic
corticosteroids*

34 (24·8%)

67 (24·2%)

54 (22·0%)

51 (35·9%)

103 (36·1%)

94 (35·9%)

Concomitant use of
immunosuppressants*†

33 (24·1%)

63 (22·7%)

53 (21·6%)

21 (14·8%)

34 (11·9%)

34 (13·0%)

8 (5·8%)

19 (6·9%)

20 (8·2%)

11 (7·7%)

28 (9·8%)

28 (10·7%)

Concomitant use of systemic
corticosteroids and
immunosuppressants
Prednisone-equivalent dose, mg/day

20·0
(15·0–30·0)

15·0
(10·0–25·0)

20·0
(10·0–25·0)

20·0
(10·0–20·0)

20·0
(10·0–20·0)

15·0
(10·0–20·0)

Number of previous biologic agents‡
0

137 (100·0%)

275 (99·3%)

245 (100·0%)

3 (2·1%)

2 (0·7%)

3 (1·1%)

46 (32·4%)

98 (34·4%)

80 (30·5%)

··

45 (31·7%)

109 (38·2%)

90 (34·4%)

··

48 (33·8%)

76 (26·7%)

89 (34·0%)

2 (0·7%)

··

130 (91·5%)

266 (93·3%)

242 (92·4%)

··

1 (0·4%)

··

85 (59·9%)

145 (50·9%)

164 (62·6%)

··

1 (0·4%)

··

76 (53·5%)

128 (44·9%)

147 (56·1%)

··

1 (0·4%)

··

64 (45·1%)

113 (39·6%)

120 (45·8%)

1

··

1 (0·4%)

··

2

··

1 (0·4%)

≥3

··

··

Previous use of at least one TNF
antagonist

··

Previous use of vedolizumab
Previous use of at least one TNF
antagonist and vedolizumab
Previous failure of a TNF antagonist
and vedolizumab

Data are n (%), mean (SD), or median (IQR). TNF=tumour necrosis factor. *Corticosteroids or immunosuppressants, but not both. †6-mercaptopurine, azathioprine,
and methotrexate. ‡Patients who received biologic agents in induction study A and patients who did not receive biologic agents in induction study B were ineligible.

Table 1: Baseline demographics and characteristics of patients in induction studies A and B

and placebo group, and between the filgotinib 100 mg
and placebo group in induction studies A and B and
between the filgotinib 200 mg and the respective
placebo group, and the filgotinib 100 mg and the
respective placebo group in the maintenance study.
Continuous exploratory efficacy endpoints were either
summarised by descriptive statistics or by an analysis
of covariance model adjusting for stratification factors
and baseline values. A last observation carried forward
approach was used to impute the missing values
for con
tinuous endpoints in the model. Baseline
demographics and characteristics, safety data, and
pharmacokinetic data were summarised by descriptive
statistics. Pharmacokinetic analyses were done by use of
non-compartmental analyses in conjunction with a nonlinear mixed-effects population modelling approach.
Statistical analyses were done by use of SAS version 9.4.
This study is registered with ClinicalTrials.gov,
NCT02914522.

Role of the funding source
The funder of the study was involved in the study design
and the data collection and analysis. The study funder
provided funding for medical writing assistance with
manuscript preparation.

Results
Between Nov 14, 2016, and March 31, 2020, we screened
2040 patients for eligibility into the induction studies.
1090 patients were screened for eligibility into induction
study A, of whom 659 biologic-naive patients were
enrolled and randomly assigned to receive filgotinib
100 mg (n=277), filgotinib 200 mg (n=245), or pla
cebo (n=137). 950 patients were screened for eligibility
into induction study B, of whom 689 biologic-experienced
patients were enrolled and randomly assigned to receive
filgotinib 100 mg (n=285), filgotinib 200 mg (n=262), or
placebo (n=142; figure 1). Following the efficacy assess
ment at week 10, 664 patients entered the maintenance
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A

Proportion of patients (%)

100
80
60
40
20
0

B
Placebo
Filgotinib 100 mg
Filgotinib 200 mg
Absolute difference 10·8% (95% CI 2·1 to 19·5)
p=0·0157

Absolute difference 7·2% (95% CI 1·6 to 12·8)
p=0·0103

Absolute difference 3·8% (95% CI –4·3 to 12·0)
p=0·3379

Absolute difference 5·2% (95% CI 0·0 to 10·5)
p=0·0645

15·3%

19·1%

26·1%
4·2%

21/137

53/277

64/245

C

6/142

9·5%

11·5%

27/285

30/262

D

Proportion of patients (%)

100
80
60
40
20
0

Absolute difference 12·1% (95% CI 3·8 to 20·4)
p=0·0053

Absolute difference 5·3% (95% CI –0·1 to 10·7)
p=0·0393

Absolute difference 4·6% (95% CI –3·1 to 12·2)
p=0·2295

Absolute difference 1·7% (95% CI –3·1 to 6·6)
p=0·5308

24·5%
12·4%

17/137

17·0%

47/277

60/245

E

4·2%

6·0%

6/142

17/285

9·5%

25/262

F

Proportion of patients (%)

100
80
60
40
20
0

Absolute difference 8·6% (95% CI 2·9 to 14·3)
p=0·0047

Absolute difference 1·3% (95% CI –2·5 to 5·1)
p=0·4269

Absolute difference 2·1% (95% CI –2·6 to 6·8)
p=0·3495

Absolute difference 0·0% (95% CI –3·4 to 3·4)
p=0·9987

3·6%

5·8%

5/137

16/277

12·2%

30/245

G

2·1%

2·1%

3·4%

3/142

6/285

9/262

H

Proportion of patients (%)

100
80
60
40
20
0

Absolute difference 19·0% (95% CI 9·9 to 28·2)
p<0·0001

Absolute difference 11·4% (95% CI 4·2 to 18·6)
p=0·0019

Absolute difference 7·8% (95% CI –0·7 to 16·2)
p=0·0672
35·1%

Absolute difference 5·2% (95% CI –1·4 to 11·8)
p=0·1286

16·1%

22/137

23·8%
8·5%

66/277

86/245

12/142

13·7%

39/285

19·8%

52/262

Figure 2: Remission and key secondary endpoints at week 10 in patients given filgotinib or placebo for
ulcerative colitis (induction studies)
(A) Clinical remission in biologic-naive patients. (B) Clinical remission in biologic-experienced patients. (C) MCS
remission in biologic-naive patients. (D) MCS remission in biologic-experienced patients. (E) Endoscopic remission
in biologic-naive patients. (F) Endoscopic remission in biologic-experienced patients. (G) Histological remission in
biologic-naive patients. (H) Histological remission in biologic-experienced patients. Error bars indicate 95% CI.
MCS=Mayo Clinic Score.
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study (391 [58·9%] of 664 patients were from induction
study A and 273 [41·1%] were from induction study B).
93 patients who had responded while receiving placebo
in the induction study were assigned to continue placebo.
270 patients who had received filgotinib 100 mg in
the induction study were randomly assigned to receive
filgotinib 100 mg (n=179) or placebo (n=91). 301 patients
who had received filgotinib 200 mg in the induction
study were randomly assigned to receive filgotinib
200 mg (n=202) or placebo (n=99). Full details of the
groups in the main
tenance study, including patient
discontinuations, can be found in the appendix (p 11).
Baseline characteristics were similar between treat
ment groups in each induction study (table 1). 55·8% of
biologic-naive patients (induction study A) and 77·8% of
biologic-experienced patients (induction study B) had
a Mayo endoscopic subscore of 3. Median baseline
prednisone-equivalent dose was 20·0 mg/day in both
induction trials. 30·7% of biologic-naive patients were
receiving systemic corticosteroids at baseline compared
with 45·7% of biologic-experienced patients. 43·1% of
biologic-experienced patients had failure of both a TNF
antagonist and vedolizumab. The baseline characteristics
of patients who participated in the maintenance study
were similar across treatment groups (appendix p 16).
In induction study A, 34 patients discontinued
treatment (17 patients assigned to filgotinib 100 mg
[ten patient decisions, five adverse events, one lost to
follow-up, one protocol violation]; eight patients assigned
to filgotinib 200 mg [four patient decisions, three adverse
events, one non-compliance with study drug]; and
nine patients assigned to placebo [four patient decisions,
three adverse events, one loss to follow-up, one protocol
violation]). 625 patients from induction study A com
pleted study drug or placebo to week 10. In induction
study B, 54 patients discontinued treatment (20 patients
assigned to filgotinib 100 mg [14 adverse events,
three patient decisions, one protocol violation, one
investigator’s decision, one pregnancy]; 20 patients
assigned to filgotinib 200 mg [15 adverse events,
five patient decisions]; and 14 patients assigned to placebo
[ten adverse events, three patient decisions, one protocol
violation]). 635 patients from induction study B com
pleted study drug or placebo to week 10. In the
maintenance study, 263 patients discontinued treatment
(75 patients assigned to filgotinib 100 mg, 52 patients
assigned to filgotinib 200 mg, and 136 patients assigned
to placebo). 401 patients completed the maintenance
study to week 58. The most common reason for study
drug discontinuation in the maintenance study for all
treatment groups was disease worsening (for full details
see appendix p 11).
In induction study A, 64 (26·1%) of 245 biologic-naive
patients given filgotinib 200 mg had clinical remission at
week 10, compared with 21 (15·3%) of 137 patients given
placebo (absolute difference 10·8%, 95% CI 2·1–19·5;
p=0·0157, figure 2A). In induction study B, 30 (11·5%) of
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A

Proportion of patients (%)

100
80
60

B
Placebo
Filgotinib 100 mg
Filgotinib 200 mg
Absolute difference 10·4%
(95% CI 0·0 to 20·7)
p=0·0420

40
20
0

Absolute difference 26·0%
(95% CI 16·0 to 35·9)
p<0·0001

Absolute difference 8·2%
(95% CI –4·2 to 20·6)
p=0·1265

37·2%

23·8%
13·5%

12/89

11·2%

41/172

11/98

5·4%

74/199

C

2/37

13·6%

11/81

Absolute difference 20·8%
(95% CI 7·7 to 33·9)
p=0·0055
27·2%
6·4%

3/47

25/92

D

Proportion of patients (%)

100
80
60

Absolute difference 13·0%
(95% CI 5·3 to 20·6)
p=0·0024

40

Absolute difference 0·9%
(95% CI –7·0 to 8·7)
p=0·7951

20

7·9%

8·7%

5·1%

7/89

15/172

5/98

0

Absolute difference 9·2%
(95% CI –1·1 to 19·5)
p=0·0658

18·1%

13·5%

36/199

E

12/89

Absolute difference 25·5%
(95% CI 16·0 to 35·0)
p<0·0001
34·7%

22·7%
9·2%

39/172

9/98

69/199

F

Proportion of patients (%)

100
80
60
40

Absolute difference 5·5%
(95% CI –2·9 to 13·9)
p=0·1808

20

7·9%

0

7/89

13·4%

23/172

Absolute difference 9·5%
(95% CI 1·8 to 17·1)
p=0·0157
15·6%

Absolute difference 9·9%
(95% CI –1·3 to 21·2)
p=0·0521

Absolute difference 24·9%
(95% CI 14·6 to 35·2)
p<0·0001
38·2%

27·9%
18·0%

13·3%

6·1%
6/98

31/199

16/89

48/172

13/98

76/199

Figure 3: Proportion of patients with clinical remission and key secondary efficacy endpoints at week 58 in patients given filgotinib or placebo for ulcerative
colitis (maintenance study)
(A) Clinical remission. (B) 6-month corticosteroid-free remission. (C) Sustained clinical remission. (D) MCS remission. (E) Endoscopic remission. (F) Histological
remission. Error bars indicate 95% CI. MCS=Mayo Clinic Score.

262 biologic-experienced patients given filgotinib 200 mg
had clinical remission at week 10, compared with
six (4·2%) of 142 patients given placebo (absolute dif
ference 7·2%, 95% CI 1·6–12·8; p=0·0103, figure 2B). The
differences in clinical remission between filgotinib 100 mg
and placebo were not statistically significant at week 10 in
either induction study (biologic-naive filgotinib 100 mg vs
placebo p=0·3379, biologic-experienced filgotinib 100 mg
vs placebo p=0·0645; figure 2A).
In the maintenance study, 74 (37·2%) of 199 patients in
the filgotinib 200 mg group had clinical remission at
week 58, compared with 11 (11·2%) of 98 patients
assigned to placebo (absolute difference 26·0%, 95% CI
16·0–35·9; p<0·0001, figure 3A). 41 (23·8%) of
172 patients assigned to filgotinib 100 mg had clinical
remission at week 58 compared with 11 (13·5%) of

81 patients assigned to placebo, and this difference
was statistically significant (absolute difference 10·4%,
95% CI 0·0–20·7; p=0·0420, figure 3A).
36 (62·1%) of 58 patients given filgotinib 200 mg and
five (13·9%) of 36 patients given placebo were in clinical
remission at both week 10 and week 58. 15 (27·8%) of
54 patients in the filgotinib 100 mg group and
seven (29·2%) of 24 patients in the placebo group were
in clinical remission at both timepoints.
The treatment effect of filgotinib 200 mg on clinical
remission relative to placebo at week 58 was consistent
across the prespecified subgroups (biologic-naive vs
biologic-experienced patients, TNF antagonist failure
status, vedolizumab failure status, and dual refractory
status [failure of both a TNF antagonist and vedolizumab];
appendix p 12).
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Placebo
(n=279)
Total duration of study drug exposure,
weeks

Filgotinib 100 mg
(n=562)

Filgotinib 200 mg
(n=507)

10·7 (1·93)

10·8 (1·91)

10·8 (1·58)

Treatment-emergent adverse events
Adverse events

157 (56·3%)

283 (50·4%)

272 (53·6%)

Serious adverse events

13 (4·7%)

28 (5·0%)

22 (4·3%)

Adverse events leading to study drug
discontinuation

14 (5·0%)

20 (3·6%)

23 (4·5%)

Deaths

0

0

0

Adverse events of interest
Infections

39 (14·0%)

82 (14·6%)

92 (18·1%)

Serious infections

3 (1·1%)

6 (1·1%)

3 (0·6%)

Herpes zoster

0

1 (0·2%)

3 (0·6%)

Opportunistic infections

0

0

1 (0·2%)

Malignancies*

0

1 (0·2%)

1 (0·2%)

Non-melanoma skin cancer

1 (0·4%)

0

2 (0·4%)

Gastrointestinal perforation

1 (0·4%)

0

0

Venous thrombosis excluding
pulmonary embolism

0

0

0

Pulmonary embolism

0

0

1 (0·2%)

Arterial thrombosis

0

0

0

Cerebrovascular events

1 (0·4%)

0

0

Abnormal laboratory test results†
Haemoglobin <8g/dL

8 (2·9%)

10 (1·8%)

10 (2·0%)

WBC <2000/mm³

1 (0·4%)

1 (0·2%)

3 (0·6%)

Neutrophils <1000/mm³

2 (0·7%)

7 (1·3%)

3 (0·6%)

Lymphocytes <500/mm³

6 (2·2%)

10 (1·8%)

11 (2·2%)

AST >5 × ULN

0

1 (0·2%)

1 (0·2%)

ALT >5 × ULN

2 (0·7%)

0

1 (0·2%)

CK >5 × ULN

0

4 (0·7%)

7 (1·4%)

Triglycerides >500 mg/dL

0

2 (0·4%)

1 (0·2%)

Data are n (%) or mean (SD). ALT=alanine aminotransferase. AST=aspartate aminotransferase. CK=creatine kinase.
ULN=upper limit of normal. WBC=white blood cells. *Excluding non-melanoma skin cancer. †A treatment-emergent
laboratory abnormality was defined as an increase of at least one grade from baseline at any post-baseline timepoint
up to the maintenance first dose date or 30 days after the induction last dose date, whichever was earlier.

Table 2: Summary of safety outcomes in induction studies A and B combined

A greater proportion of biologic-naive patients given
filgotinib 200 mg than those given placebo had MCS
remission, endoscopic remission, histologic remission,
and MCS remission (alternative definition) at week 10
(figure 2; appendix p 13). There were no statistically
significant differences in these key secondary endpoints
for filgotinib 100 mg relative to placebo in biologic-naive
patients. In biologic-experienced patients, differences in
prespecified secondary endpoints between patients given
filgotinib (either dose) and patients given placebo were
not statistically significant at week 10 (figure 2).
At week 58, a greater proportion of patients who
received filgotinib 200 mg had 6-month corticosteroid-free
clinical remission, sustained clinical remission, MCS
remission, endoscopic remission, histologic remission,
and MCS remission (alternative definition) than those
who received placebo (figure 3; appendix p 13). There
were no significant differences in the proportion of
2380

patients with these endpoints between patients given
filgotinib 100 mg and those given placebo (figure 3;
appendix p 13).
In both induction studies and the maintenance study, a
greater proportion of patients in the filgotinib 200 mg and
100 mg groups had an MCS response and endoscopic
improvement than in the placebo group (appendix p 14).
Changes from baseline were greater in the filgotinib
200 mg group than the placebo group in the total and all
four domain scores of the Inflammatory Bowel Disease
Questionnaire, 36-Item Short Form Survey mental com
ponent summary and physical component summary
(appendix p 17). We recorded greater improvements in
the filgotinib 200 mg group than the placebo group
in the presenteeism, work productivity loss, and activity
impairment domains of the Work Productivity and
Activity Impairment questionnaire, and the European
Quality of Life 5-Dimension questionnaire visual analogue
scale.
The treatment effect of filgotinib 200 mg compared
with placebo in all key secondary endpoints was consistent
between biologic-naive and biologic-experienced patients
at week 58 (appendix p 29). Greater proportions of
patients in the filgotinib 200 mg group than in the
respective placebo group had mucosal healing in all
studies (appendix p 15).
In the induction studies, the proportion of patients who
had treatment-emergent adverse events was similar
between the placebo, filgotinib 100 mg, and filgotinib
200 mg groups (table 2). In the maintenance study,
adverse events were reported for a similar proportion of
patients in the placebo groups and filgotinib 100 mg and
filgotinib 200 mg groups. In all three studies, most
adverse events were mild or moderate in severity. The
most frequent adverse events in the induction studies
were nasopharyngitis, headache, and ulcerative colitis
(data not shown). The most frequent adverse events in the
maintenance study were worsening of ulcerative colitis,
nasopharyngitis, arthralgia, headache, abdominal pain,
and upper respiratory tract infections (appendix p 31). The
proportion of patients who discontinued treatment owing
to adverse events was similar across treatment groups in
the induction and maintenance studies (tables 2, 3).
In the induction studies, serious adverse events occurred
in 28 (5·0%) of 562 patients given filgotinib 100 mg,
22 (4·3%) of 507 patients given filgotinib 200 mg, and
13 (4·7%) of 279 patients given placebo (table 2). In the
maintenance study, serious adverse events were reported
in eight (4·5%) of 179 patients given filgotinib 100 mg and
seven (7·7%) of 91 patients in the respective placebo group,
by nine (4·5%) of 202 patients in the filgotinib 200 mg
group, and no patients in the respective placebo group
(table 3). Exposure-adjusted incidence rates of serious
adverse events were similar across treatment groups in the
induction and maintenance studies (appendix p 31).
The incidence of infections and serious infections was
similar between treatment groups in all three studies
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(tables 2, 3). The exposure-adjusted incidence rate of
infections and serious infections was also similar between
patients who received placebo, filgotinib 100 mg, and
filgotinib 200 mg in all three studies (appendix p 33).
Six patients from all studies had herpes zoster infec
tions, none of which were serious or complicated
(multidermatomal, disseminated, ophthalmic, or with
CNS involvement), or resulted in discontinuation of the
study drug. The exposure-adjusted incidence rate of
herpes zoster was similar across treatment groups in all
three studies (appendix p 33). One patient in induction
study A who received filgotinib 200 mg had an
opportunistic infection of mild oesophageal candidiasis
that resolved with treatment.
One patient with hypothyroidism and pulmonary
symptoms of unknown origin who was taking prednisone
and who received filgotinib 200 mg had pulmonary
embolism in induction study B. No patients who received
filgotinib 100 mg or 200 mg had venous thromboses
or pulmonary embolism in the maintenance study.
Two patients who received placebo in the induction study
and then in the maintenance study had venous
thromboses.
Non-melanoma skin cancers occurred in three patients
in the induction studies and one patient in the main
tenance study. All patients with non-melanoma skin
cancer had been previously treated with thiopurines.
Malignancies were reported in three patients (one colon
cancer in induction study A, filgotinib 100 mg [diagnosed
during the maintenance study based on findings in the
induction phase]; one breast cancer in induction study B,
filgotinib 200 mg; one malignant melanoma in the
maintenance study, filgotinib 200 mg). Other adverse
events of interest are reported in tables 2 and 3.
No deaths were reported during either induction study.
Two patients died during the maintenance study (one left
ventricular failure, one asthma), neither death was
deemed related to the study treatment by the investigator
(appendix p 10).
The proportion of patients with treatment-emergent
laboratory abnormalities (an increase of at least one
grade) was similar across studies and treatment groups
(tables 2, 3). In the induction studies, a small increase
in lipids (total cholesterol, LDL, and HDL) was observed
in the filgotinib groups (appendix p 34). In the
maintenance study, lipid concentrations remained
stable in the filgotinib groups. The proportion of
patients with abnormal creatine kinase increase was
higher in the filgotinib groups than in the placebo
groups in all three studies, but no rhabdomyolysis
associated with increased creatine kinase was reported
in patients who received filgotinib.
Data from 41 patients who participated in the pharma
cokinetic substudy suggested that the pharmacokinetics
of filgotinib and GS829845 were similar in biologicnaive and biologic-experienced patients. Filgotinib and
GS829845 exposures were approximately dose propor

Total duration of study drug
exposure, weeks

Placebo*
(n=93)

Placebo†
(n=91)

38·1 (15·2)

29·2 (18·6)

Filgotinib
Placebo‡
100 mg (n=179) (n=99)
34·5 (16·8)

28·8 (17·7)

Filgotinib
200 mg (n=202)
39·4 (14·3)

Treatment-emergent adverse events
Adverse events

57 (61·3%) 60 (65·9%) 108 (60·3%)

Serious adverse events

4 (4·3%)

7 (7·7%)

8 (4·5%)

Adverse events leading to
study drug discontinuation

3 (3·2%)

4 (4·4%)

10 (5·6%)

Deaths

0

0

0

59 (59·6%) 135 (66·8%)
0

9 (4·5%)

2 (2·0%)

7 (3·5%)

0

2 (1·0%)

Adverse events of interest
Infections

21 (22·6%)

27 (29·7%)

46 (25·7%)

Serious infections

1 (1·1%)

2 (2·2%)

3 (1·7%)

25 (25·3%)
0

71 (35·1%)

Herpes zoster

0

1 (1·1%)

0

0

1 (0·5%)

Opportunistic infections

0

0

0

0

0

Malignancies§

0

0

1 (0·6%)

0

1 (0·5%)

Non-melanoma skin
cancer

0

0

1 (0·6%)

0

0

Gastrointestinal
perforation

0

0

0

0

0

Venous thrombosis
excluding pulmonary
embolism

2 (2·2%)

0

0

0

0

Pulmonary embolism

0

0

0

0

0

Arterial thrombosis¶

0

0

1 (0·6%)

0

0

Cerebrovascular events¶

0

0

1 (0·6%)

0

0
3 (1·5%)

2 (1·0%)

Abnormal laboratory test results||
Haemoglobin <8 g/dL

0

1 (1·1%)

1 (0·6%)

1 (1·0%)

WBC <2000/mm³

0

1 (1·1%)

0

0

1 (0·5%)

Neutrophils <1000/mm³

0

2 (2·2%)

3 (1·7%)

2 (2·1%)

0

Lymphocytes <500/mm³

1 (1·1%)

1 (1·1%)

3 (1·7%)

1 (1·0%)

5 (2·5%)

AST >5 × ULN

1 (1·1%)

1 (1·1%)

1 (0·6%)

1 (1·0%)

1 (0·5%)

ALT >5 × ULN

1 (1·1%)

2 (2·2%)

3 (1·7%)

0

1 (0·5%)

CK >5 × ULN

1 (1·1%)

1 (1·1%)

2 (1·1%)

2 (2·1%)

8 (4·0%)

Triglycerides >500 mg/dL

0

1 (1·3%)

1 (0·7%)

1 (1·2%)

0

Total cholesterol
>400 mg/dL

0

0

0

0

1 (0·5%)

Data are n (%) or mean (SD). ALT=alanine aminotransferase. AST=aspartate aminotransferase. CK=creatine kinase.
ULN=upper limit of normal. WBC=white blood cells. *Patients who responded with placebo in the induction studies
and continued to receive placebo in the maintenance study. †Patients who responded with filgotinib 100 mg in the
induction studies and were randomly assigned to placebo in the maintenance study. ‡Patients who responded with
filgotinib 200 mg in the induction studies and were randomly assigned to placebo in the maintenance study.
§Excluding non-melanoma skin cancer. ¶Transient ischaemic attack was reported in one patient and was reported as
both arterial thrombosis and a cerebrovascular event. ||A treatment-emergent laboratory abnormality was defined as
an increase of at least one grade from maintenance baseline at any maintenance post-baseline timepoint up to 30 days
after the last maintenance study drug dose date. Denominator for laboratory abnormality was patients who received
at least one dose of drug with at least one post-baseline value for the variable under evaluation.

Table 3: Summary of safety outcomes in the maintenance study

tional from 100 mg to 200 mg (appendix p 35). The
median concentration at the end of the dosing interval
was similar between patients in the induction and
maintenance studies. Filgotinib and GS829845 expo
sures overlapped substantially between patients who
met the primary endpoint in either the induction or
maintenance phase and those who did not for both dose
regimens. Filgotinib exposures were similar for patients
who reported the most common adverse events or
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grade 3 or 4 laboratory abnormalities and those who
did not.

Discussion
This is the first investigation of filgotinib, a once-daily,
oral JAK1 preferential inhibitor, for the treatment of
patients with moderately to severely active ulcerative
colitis. 200 mg filgotinib was consistently efficacious for
both induction and maintenance treatment, with the
primary efficacy endpoint being met in all three studies.
Filgotinib was well tolerated at both 100 mg and 200 mg,
with serious adverse events and adverse events of
interest occurring with similar incidence to placebo.
Filgotinib was efficacious in both biologic-naive and
biologic-experienced patients, all of whom had nonresponse to other therapies and high inflammatory
burden at baseline. In particular, the proportion of
patients with severe endoscopic disease was 77·8% in
induction study B, which studied patients who had had
previous TNF antagonist or vedolizumab treatment,
indicating that this was a difficult population to treat.
43·1% of patients in induction study B had failure of both
drug classes, which could also indicate poor prognosis.
The low placebo remission rate of 4·2% observed at
week 10 also suggests that these patients were highly
treatment resistant. Despite this, we observed a clinically
relevant difference in remission rate between the
filgotinib 200 mg group and the placebo group at week 10.
In addition, a greater proportion of biologic-naive and
biologic-experienced patients had clinical and endoscopic
improvement after receiving filgotinib 200 mg for
10 weeks compared with those who received placebo.
Efficacy was also reported in the maintenance study, in
which the proportion of patients with clinical remission
at week 58 was significantly higher in those who
continued filgotinib 200 mg than those assigned to
placebo. In subgroup analyses of clinical remission at
week 58, efficacy of filgotinib 200 mg was observed for
both biologic-naive and biologic-experienced patients.
All of the prespecified secondary endpoints of MCS
remission, endoscopic remission, and histologic remis
sion were met at week 10 in biologic-naive patients and
at week 58 in patients given filgotinib 200 mg. These
results are encouraging given the stringent definitions
of endoscopic remission (Mayo endoscopic subscore
of 0) and histological remission (absence of neutrophils
in the lamina propria or the epithelium) used. In
addition, a significantly greater proportion of patients
given filgotinib 200 mg than placebo had 6-month
corticosteroid-free remission at week 58, despite the
stringent definition of corticosteroid-free remission
used. The results for filgotinib 100 mg versus 200 mg
suggest a clear dose-response relationship, with the
100 mg dose not showing significant differences
versus placebo in the induction studies; this sug
gestion is supported by both MCS response and
endoscopic improvement data. These data could warrant
2382

investigation of doses higher than 200 mg; however,
higher doses could negate filgotinib’s preferential
inhibition of the JAK1 subtype or compromise the safety
profile. Although the secondary endpoint of endoscopic
remission was not reported in induction study B,
as previously noted, this was a stringent definition of
success in a patient population that was difficult to
treat. By contrast, analysis of the outcome of histologic
remission identified a benefit of the 200 mg dose in
these patients, suggesting that histopathology might be
a more sensitive measure of treatment response.
Filgotinib was well tolerated at both doses and over
all three studies. Rates of serious adverse events and
discontinuations due to adverse events were similar
between the filgotinib and placebo groups. Consistent
with findings in patients with rheumatoid arthritis
given filgotinib,16–18 herpes zoster infections and serious
infections were observed at low and similar rates in all
treatment groups. This observation was despite the
fact that concomitant therapy of corticosteroids and
immunosuppressants was permitted, by contrast with a
phase 3 trial of tofacitinib,10 in which immunosuppres
sants were discontinued at induction screening. One
venous thromboembolic event (pulmonary embolism)
was reported in the filgotinib group, but the elevated risk
of thromboembolism in patients with ulcerative colitis
has been well documented,27 and two venous thromboses
occurred in the placebo group in the maintenance
study after induction placebo. Malignancies and nonmelanoma skin cancers each occurred in three patients
treated with filgotinib.
Safety concerns outside those reported in this trial
are being investigated. Findings in animal studies of
filgotinib included impaired spermatogenesis and histo
pathological effects on male reproductive organs (testes
and epididymis).28 Two clinical studies investigating the
potential translation of these observations to men are
underway (NCT03926195, NCT03201445).
Key strengths of our study were the large sample
size, and the simple dosing regimen that allowed
patients to continue receiving the same oral dose of
drug daily for both induction and maintenance, with
no need for dose modification. The study also had
some limitations, specifically, the short duration of the
assessments inherent to randomised controlled trials.
A separate, long-term extension study (SELECTIONLTE;
NCT02914535) is underway. Further studies would be
required to determine the effectiveness and safety of
filgotinib in real-world clinical practice. The absence
of dose intensification or extended therapy beyond
week 10 for induction non-responders also requires
evaluation in further trials.
Treatment with filgotinib 200 mg for up to 58 weeks
was efficacious for induction and maintenance of clinical
remission in both biologic-naive and biologic-experienced
patients with moderately to severely active ulcerative
colitis. Filgotinib was well tolerated.
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